Neurology 2-Plex A (Aβ40, Aβ42)

Aβ40 and Aβ42: Biomarkers for Alzheimer’s Disease

Aβ40 and Aβ42, derived from the amyloid precursor protein (APP), are biomarkers associated with Alzheimer’s disease (AD), mild cognitive impairment, vascular dementia, and cognitive disorders.

Aβ peptides, including Aβ38, Aβ40, and Aβ42, are predominantly synthesized in the brain, with Aβ40 being the major component. The cleavage of APP by beta-secretase followed by gamma-secretase leads to the production of Aβ40 and Aβ42. Accumulation of Aβ peptides, particularly Aβ40, as extracellular plaques is a hallmark of AD pathology, initiating neurodegenerative processes.

Aβ42 has garnered significant attention due to its correlation with AD onset. Its CSF levels serve as a clinically validated marker for AD diagnosis and progression. Although concentrations of Aβ42 in blood are markedly lower than in CSF, there is growing interest in measuring blood levels for research and diagnostic purposes. Thus, reliable measurement of Aβ42 necessitates high analytical sensitivity. In contrast, Aβ40, being more abundant in both CSF and blood, has also shown promise as a biomarker for AD progression, with recent studies highlighting its potential significance, particularly in the context of the Aβ42/Aβ40 ratio.

Understanding the roles of Aβ40 and Aβ42 as biomarkers is crucial for diagnosing and monitoring Alzheimer’s disease and related cognitive disorders, paving the way for improved treatment strategies and interventions.

Applications and Intended Use

The Neurology 2-Plex A Advantage PLUS assay is an ultra-sensitive immunoassay intended for the measurement of Aβ40 and Aβ42 in human CSF and EDTA plasma samples.

Compatible Instruments

Advantage PLUS: HD-X

Kit Contents

The assay kit includes all necessary reagents and controls to perform 96 tests, making it easy to use and compatible with various sample types.